Sodium acetate
BLOOD AND BLOOD FORMING ORGANS
Also known as: acetic acid, sodium salt, anhydrous sodium acetate, sodium acetate anhydrous
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Sodium acetate is a drug catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 2 molecular targets, including CA1 and NCE103.
- Molecular targets: CA1 and NCE103 (2 listed in DrugCentral).
- ATC code: B05XA08 (Electrolyte solutions).
- Molecular formula: C2H3NaO2; molecular weight 82.03 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Contraindications (23)
- Acute nephropathy
- Anuria
- Azotemia
- Classical phenylketonuria
- Complete atrioventricular block
- Congenital myotonia, autosomal dominant form
- End stage renal disease
- Familial hyperkalemic periodic paralysis
- Heart disease
- Humoral hypercalcemia of malignancy
- Hypercalcemia
- Hypercalciuria
- Hyperchloremia
- Hyperkalemia
- Hyporeninemic hypoaldosteronism
- Kidney disease
- Kidney stone
- Oliguria
- Poisoning by digitalis glycoside
- Sarcoidosis
- Severe dehydration
- Third degree burn injury
- Ventricular fibrillation
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Carbonic anhydrase 1 | CA1 | unknown | Ki 4.97 |
| Carbonic anhydrase | NCE103 | unknown | Ki 4.44 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1983-05-04 | FDA | — | HOSPIRA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B05XA08 | BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › I.V. SOLUTION ADDITIVES › Electrolyte solutions |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxic anterior segment syndrome | 1275.3 |
| Endophthalmitis | 386.6 |
| Post procedural complication | 173.3 |
| Anterior chamber cell | 169.4 |
| Cataract operation complication | 140.7 |
| Eye inflammation | 117.1 |
| Anterior chamber disorder | 83.6 |
| Corneal oedema | 77.3 |
| Keratitis | 74.1 |
| Anterior chamber inflammation | 63.2 |
| Iridocyclitis | 52.9 |
| Intraocular pressure increased | 51.5 |
Chemical structure
| Molecular formula | C2H3NaO2 |
|---|---|
| Molecular weight | 82.03 g/mol |
| CAS number | 127-09-3 |
| InChIKey | — |
| PubChem CID | 517045 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
How does Sodium acetate work?
Its molecular targets in DrugCentral include CA1 and NCE103.
When was Sodium acetate first approved?
Sodium acetate was first approved by the FDA in 1983.
What is the chemical formula of Sodium acetate?
Sodium acetate has the molecular formula C2H3NaO2 and a molecular weight of 82.03 g/mol.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4203 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1354 — compound record and bioactivity
- PubChem CID 517045 — chemical identifiers
- DrugBank DB09395 — drug record
- FDA UNII 4550K0SC9B — substance identity
- DailyMed: FDA labels for Sodium acetate — current prescribing information (label search)
- UniProt P00915 (CA1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.